142 related articles for article (PubMed ID: 15346853)
1. A Bayesian approach to tracking patients having changing pharmacokinetic parameters.
Bayard DS; Jelliffe RW
J Pharmacokinet Pharmacodyn; 2004 Feb; 31(1):75-107. PubMed ID: 15346853
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Bayesian estimation of pharmacokinetic parameters.
Tsuchiwata S; Mihara K; Yafune A; Ogata H
Ther Drug Monit; 2005 Feb; 27(1):18-24. PubMed ID: 15665741
[TBL] [Abstract][Full Text] [Related]
3. A Bayesian formulation of the Kalman filter applied to the estimation of individual pharmacokinetic parameters.
Botsman K; Tickle K; Smith JD
Comput Biomed Res; 1997 Apr; 30(2):83-94. PubMed ID: 9167082
[TBL] [Abstract][Full Text] [Related]
4. Evaluation and comparison of simple multiple model, richer data multiple model, and sequential interacting multiple model (IMM) Bayesian analyses of gentamicin and vancomycin data collected from patients undergoing cardiothoracic surgery.
Macdonald I; Staatz CE; Jelliffe RW; Thomson AH
Ther Drug Monit; 2008 Feb; 30(1):67-74. PubMed ID: 18223465
[TBL] [Abstract][Full Text] [Related]
5. A Bayesian approach for the estimation of pharmacokinetic parameters in children.
Mahmood I
Am J Ther; 2003; 10(2):88-92. PubMed ID: 12629586
[TBL] [Abstract][Full Text] [Related]
6. Developing population pharmacokinetic parameters for high-dose methotrexate therapy: implication of correlations among developed parameters for individual parameter estimation using the Bayesian least-squares method.
Watanabe M; Fukuoka N; Takeuchi T; Yamaguchi K; Motoki T; Tanaka H; Kosaka S; Houchi H
Biol Pharm Bull; 2014; 37(6):916-21. PubMed ID: 24882404
[TBL] [Abstract][Full Text] [Related]
7. Easy and reliable maximum a posteriori Bayesian estimation of pharmacokinetic parameters with the open-source R package mapbayr.
Le Louedec F; Puisset F; Thomas F; Chatelut É; White-Koning M
CPT Pharmacometrics Syst Pharmacol; 2021 Oct; 10(10):1208-1220. PubMed ID: 34342170
[TBL] [Abstract][Full Text] [Related]
8. Stochastic optimization algorithms of a Bayesian design criterion for Bayesian parameter estimation of nonlinear regression models: application in pharmacokinetics.
Merlé Y; Mentré F
Math Biosci; 1997 Aug; 144(1):45-70. PubMed ID: 9232968
[TBL] [Abstract][Full Text] [Related]
9. Bayesian estimation of methotrexate pharmacokinetic parameters and area under the curve in children and young adults with localised osteosarcoma.
Rousseau A; Sabot C; Delepine N; Delepine G; Debord J; Lachâtre G; Marquet P
Clin Pharmacokinet; 2002; 41(13):1095-104. PubMed ID: 12403645
[TBL] [Abstract][Full Text] [Related]
10. Patient characteristics influencing ciclosporin pharmacokinetics and accurate Bayesian estimation of ciclosporin exposure in heart, lung and kidney transplant patients.
Saint-Marcoux F; Marquet P; Jacqz-Aigrain E; Bernard N; Thiry P; Le Meur Y; Rousseau A
Clin Pharmacokinet; 2006; 45(9):905-22. PubMed ID: 16928152
[TBL] [Abstract][Full Text] [Related]
11. A Hybrid Model Associating Population Pharmacokinetics with Machine Learning: A Case Study with Iohexol Clearance Estimation.
Destere A; Marquet P; Gandonnière CS; Åsberg A; Loustaud-Ratti V; Carrier P; Ehrmann S; Guellec CB; Premaud A; Woillard JB
Clin Pharmacokinet; 2022 Aug; 61(8):1157-1165. PubMed ID: 35641861
[TBL] [Abstract][Full Text] [Related]
12. Bayesian design criteria: computation, comparison, and application to a pharmacokinetic and a pharmacodynamic model.
Merlé Y; Mentré F
J Pharmacokinet Biopharm; 1995 Feb; 23(1):101-25. PubMed ID: 8576840
[TBL] [Abstract][Full Text] [Related]
13. Individualising aminoglycoside dosage regimens after therapeutic drug monitoring: simple or complex pharmacokinetic methods?
Tod MM; Padoin C; Petitjean O
Clin Pharmacokinet; 2001; 40(11):803-14. PubMed ID: 11735603
[TBL] [Abstract][Full Text] [Related]
14. [Estimation of individual pharmacokinetic parameters using maximum a posteriori Bayesian method with D-optimal sampling strategy].
Ding JJ; Jiao Z; Wang Y
Yao Xue Xue Bao; 2011 Dec; 46(12):1493-500. PubMed ID: 22375425
[TBL] [Abstract][Full Text] [Related]
15. Maximum-likelihood versus maximum a posteriori parameter estimation of physiological system models: the C-peptide impulse response case study.
Sparacino G; Tombolato C; Cobelli C
IEEE Trans Biomed Eng; 2000 Jun; 47(6):801-11. PubMed ID: 10833855
[TBL] [Abstract][Full Text] [Related]
16. Predictive performance of Sawchuk-Zaske and Bayesian dosing methods for tobramycin.
Rodvold KA; Blum RA
J Clin Pharmacol; 1987; 27(5):419-24. PubMed ID: 3693587
[TBL] [Abstract][Full Text] [Related]
17. Mixed Bayesian networks: a mixture of Gaussian distributions.
Chevrolat JP; Rutigliano F; Golmard JL
Methods Inf Med; 1994 Dec; 33(5):535-42. PubMed ID: 7869953
[TBL] [Abstract][Full Text] [Related]
18. Diazepam pharamacokinetics from preclinical to phase I using a Bayesian population physiologically based pharmacokinetic model with informative prior distributions in WinBUGS.
Gueorguieva I; Aarons L; Rowland M
J Pharmacokinet Pharmacodyn; 2006 Oct; 33(5):571-94. PubMed ID: 16810558
[TBL] [Abstract][Full Text] [Related]
19. The estimation of population pharmacokinetic parameters using an EM algorithm.
Aarons L
Comput Methods Programs Biomed; 1993 Sep; 41(1):9-16. PubMed ID: 8275683
[TBL] [Abstract][Full Text] [Related]
20. [Can we use a Bayesian method to build a pharmacokinetic population in two steps?].
Cabelguenne D; Bleyzac N; Pivot C; Maire P
Therapie; 2000; 55(2):277-82. PubMed ID: 10967700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
